Pharma Manufacturing Outsourcing (CDMO)
All research in Pharma Manufacturing Outsourcing (CDMO) — 3 reports.
WuXi XDC is a Hong Kong-listed bioconjugate CRDMO spun out of the WuXi complex that turns ADC discovery and CMC work into higher-value late-stage and commercial manufacturing, reaching RMB 5.94 billion of 2025 revenue. The investment debate centers on price rather than ADC demand: 2025 backlog grew 50.3% to US$1.489 billion and global market share climbed from 9.9% in 2022 to more than 24%, yet the stock trades around 37x trailing and 24x 2026 earnings while carrying a persistent WuXi geopolitical discount and a capex-heavy pivot into overseas commercial supply. Rating Hold: the ADC CRDMO franchise is strong and still scaling, but the current price already anticipates a large share of the next commercial leg.
WuXi Biologics is a global biologics CRDMO platform that uses a win-the-molecule model to carry early-stage programs all the way to late-stage commercial manufacturing, converting them into sticky back-end revenue. 2025 revenue reached RMB 21.79 billion, up 16.7% year on year, with back-end manufacturing already at 43.4% of revenue; yet 58.1% of revenue comes from North America, and the valuation is pinned at roughly 22x trailing earnings by a BIOSECURE-driven geopolitical discount. Rating Hold: manufacturing delivery is proven, but listing risk is not yet resolved and the margin of safety remains thin.
Lonza Group is a Basel-based Swiss biopharmaceutical CDMO founded in 1897 and now the world's second-largest biologics manufacturing outsourcer, with 2025 revenue of CHF 6.53B split between Biologics (70%, mAb / ADC / CGT / mRNA manufacturing) and Capsules & Health Ingredients (30%). The core thesis is that its 2024 strategic reset, including the USD 1.2B acquisition of Roche's Vacaville site in California, the divestiture of Specialty Ingredients, and the arrival of CEO Wolfgang Wienand, positions Lonza as one of only two scaled mammalian biologics capacity leaders above 200,000L, alongside Samsung Biologics, with additional policy tailwinds from the BIOSECURE Act against WuXi Biologics. Rating Hold: a high-quality CDMO compounder with visible recovery and upside catalysts, but a thin margin of safety at the current price.